NL-OMON53879
Not yet recruiting
Not Applicable
Can we use a simple blood test to reduce patients who will receive neoadjuvant chemoradiation by timely identification of radiotherapy-resistant rectal cancers? - MeD-Seq Rectal
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rectal cancer
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 75
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age \>18 \- Histologically confirmed rectal adenocarcinoma \- Scheduled for
- •neoadjuvant chemoradiation
Exclusion Criteria
- •\- Scheduled to another neoadjuvant schedule that comprises systemic
- •chemotherapy or short\-course radiation
- •\- Not able to read or understand Dutch language or mentally incompetent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal StudyPathological Response Rate, Circulating Tumour DNANCT06035471Erasmus Medical Center75
Completed
Not Applicable
Bowel Cancer Screening with a Blood Test.ACTRN12615000299505Erin Symonds240
Completed
Not Applicable
blood test to detect the presence or absence of cancerHealth Condition 1: C00-D49- NeoplasmsCTRI/2019/01/017166Epigeneres Biotech Pvt Ltd1,000
Unknown
Not Applicable
A blood test to detect the presence or absence of cancerCTRI/2018/07/015116Epigeneres Biotech Pvt Ltd24
Completed
Not Applicable
Test of re-verification of blood AGEs lowering effect (CML, 3-DG) and evaluation of effectiveness to the skins by intake of test food for 12 weeksHealthy adultJPRN-UMIN000042184EZAKI GLICO Co., Ltd.44